drug

Nicotine transdermal patch

nicotine transdermal patch
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by National Institute on Drug Abuse (NIDA)
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Effect of Nicotine Transdermal Patch on Cognitive Function and Glycolipid Metabolism in Non-smoking Schizophrenia
NCT05301660Early Phase 1Unknown
Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1
NCT00124683Phase 2Completed

KOLs & investigators

1
Tony P George, M.D.KOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
National Institute on Drug Abuse (NIDA)
company
trial
Effect of Nicotine Transdermal Patch on Cognitive Function and Glycolipid Metabolism in Non-smoking Schizophrenia
EARLY_PHASE1
trial
Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1
PHASE2
trial
indication
Schizophrenia
indication
Tobacco Use Disorder
indication
Tobacco Use Cessation
indication
Schizophrenia
indication
KOL
Tony P George, M.D.
KOL score 5
person